GrowLab Pharmaceuticals is a leading biopharmaceutical company that manufactures cGMP compliant phytocannabinoids derived therapeutic formulations from its proprietary DNA-specific medical cannabis strains. Two of our strains, namely; Comacadine® and Grolatine® have been scientifically researched and tested for safe use as alternative/biopharmaceutical medicines by people who suffer from diseases such as: Diabetes; Cancer; Sickle Cell Disease; Epilepsy; Chronic Pain; Glaucoma; PTSD; Depression; Schizophrenia; HIV/AIDS; Ulcerative Colitis.
GrowLab Pharmaceuticals holds a Prohibited Drug Operator License, through a wholly owned subsidiary company called Graft (Pty) Limited, granted by the Ministry of Health in Lesotho under Section 12 of the Drugs of Abuse Act of 2008 (Medicinal Cannabis License).
Approved activities under the license include: Cultivation; Manufacturing; Supply; Holding; Import, Export and Transit within, into and out of Lesotho for medicinal purposes and or scientific use and any other lawful use.
GrowLab Pharmaceuticals’ Medicinal Cannabis license is granted for 10 years renewable for every 12 months and the initial permitted area (phase 1) to operate on is 30,000m2 (3 hectares/7.4 acres) with allowance to expand production after the implementation of phase 1 by applying for grower license.
We are helping to ensure a constant supply of medicines in order to improve the quality of life of patients worldwide.
Our daily business is characterized by mutual respect, innovation, loyalty and sustainability.
By providing our customers with the best service possible, we are able to exceed expectations on a daily basis.